title: Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
abstract: Vascular calcification and kidney fibrosis are 2 important features of chronic kidney disease. Bone morphogenetic proteins/growth differentiation factors and their receptors are implicated in the pathogenesis of both processes. Modulation of the bone morphogenetic protein/growth differentiation factor pathways by a soluble chimeric protein that contains the activin receptor IIA (ActRIIA) domain and acts as an ActRIIA ligand trap for activin and other ligands could become a new therapeutic strategy for vascular calcification and kidney fibrosis in chronic kidney disease.
authors.affiliation: Division of Nephrology, Ambroise Paré Hospital, APHP, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Boulogne Billancourt/Paris, France; Inserm U-1018, Team 5, Paris-Sud University and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Villejuif, France. Electronic address: ziad.massy@aphp.fr.
authors.forename: Ziad A
authors.initials: ZA
authors.lastname: Massy
authors.affiliation: Inserm U-1018, Team 5, Paris-Sud University and Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Villejuif, France.
authors.forename: Tilman B
authors.initials: TB
authors.lastname: Drueke
mesh_terms: D029404:Activin Receptors; D028341:Activins; D006801:Humans; D008024:Ligands; D051436:Renal Insufficiency, Chronic; D015398:Signal Transduction
chemical_list: D008024:Ligands; D028341:Activins; D029404:Activin Receptors